摘要
背景:Meta分析显示血清中不与铜蓝蛋白结合的铜(非Cp Cu,也称为“游离”铜)在阿尔茨海默病(AD)患者中所占百分比较高。在AD患者中,基于非Cp Cu切断分层的遗传异质性维持了铜AD代谢亚型的存在。 目的:为了找到与铜异常相关的AD可检测代谢亚型存在的证据,我们探讨了一个同源性和特征明确的AD人群中神经影像学异质性的假设,该群体分为两组基础非Cp Cu切断。 方法:我们评估了66名患者铜,铜蓝蛋白,非铜绿假单胞菌,总Tau蛋白(h-tau),Thr181磷酸化tau蛋白(P-tau)和β-淀粉样蛋白1-42和APOE4基因型的水平AD患者,并比较“正常”和“高”非Cp铜组中分层的AD患者的脑萎缩和神经血管负荷视觉评分量表的神经影像学指数。 结果:非Cp Cu起源的AD组的分层对于内侧颞叶萎缩,脑室周围高信号,更深的高信号(包括额叶,枕颞叶和颞叶白质高信号),幕下高信号指数,而对于全球性萎缩不同。更具体地说,非高Cp铜组的AD患者全身萎缩的负担较轻(p = 0.042)。 结论:AD组间的神经影像学异质性提示AD存在铜代谢亚型;非铜铜似乎是这种铜AD的好标志。
关键词: 神经影像学异质性,铜不与铜蓝蛋白结合(非铜离子铜),阿尔茨海默病,游离铜,全球萎缩,铜。
Current Alzheimer Research
Title:Patients with Increased Non-Ceruloplasmin Copper Appear a Distinct Sub-Group of Alzheimer's Disease: A Neuroimaging Study
Volume: 14 Issue: 12
关键词: 神经影像学异质性,铜不与铜蓝蛋白结合(非铜离子铜),阿尔茨海默病,游离铜,全球萎缩,铜。
摘要: Background: Meta-analyses show that copper non-bound to ceruloplasmin (non-Cp Cu, also known as ‘free’ copper) in serum is higher in a percentage of Alzheimer's disease (AD) patients. Genetic heterogeneity in AD patients stratified on the basis of non-Cp Cu cut-off sustains the existence of a copper AD metabolic subtype.
Objective: In order to find evidence of the existence of a detectable metabolic subtype of AD associated to copper abnormalities, we explore the hypothesis of a neuroimaging pattern heterogeneity in an homogenous and well characterized AD population classified in two groups by the stratification of patients on the basis non-Cp Cu cut-off.
Method: We assessed levels of copper, ceruloplasmin, non-Cp Cu, cerebrospinal levels of total Tau protein (h-tau), Thr 181 phosphorylated tau protein (P-tau) and β-amyloid 1-42, and APOE4 genotype in 66 AD patients and compared neuroimaging indices of a visual rating scale of cerebral atrophy and neurovascular burden in AD patients stratified in ‘Normal’ and ‘High’ non-Cp Cu groups.
Results: The stratification for non-Cp Cu originated AD groups which did not differ for medial temporal lobe atrophy, periventricular hyperintensities, deeper hyperintensities (including frontal, parietooccipital and temporal white matter hyperintensities), infratentorial hyperintensities indices, while they differed for global atrophy. More specifically, AD patients within the high non-Cp Cu group had a less severe burden of global atrophy (p=0.042).
Conclusion: This neuroimaging heterogeneity between AD groups is suggestive of the existence of a copper metabolic subtype of AD; non-Cp Cu appears a good marker of this copper AD.
Export Options
About this article
Cite this article as:
Patients with Increased Non-Ceruloplasmin Copper Appear a Distinct Sub-Group of Alzheimer's Disease: A Neuroimaging Study, Current Alzheimer Research 2017; 14 (12) . https://dx.doi.org/10.2174/1567205014666170623125156
DOI https://dx.doi.org/10.2174/1567205014666170623125156 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mitochondria as a Therapeutic Target in Alzheimers Disease and Diabetes
CNS & Neurological Disorders - Drug Targets Neuronal and Vascular Oxidative Stress in Alzheimers Disease
Current Neuropharmacology Development, Application, and Results from a Precision-medicine Platform that Personalizes Multi-modal Treatment Plans for Mild Alzheimer’s Disease and At-risk Individuals
Current Aging Science Antipsychotics for the Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD)
Current Neuropharmacology Focus on the Different Projects of Telemedicine Centered on the Elderly In France
Current Aging Science Aging and Neuroinflammatory Disorders: New Biomarkers and Therapeutic Targets
Current Pharmaceutical Design Anti-inflammatory strategies in stroke: a potential therapeutic target
Current Vascular Pharmacology Blood Brain Barrier and Alzheimer’s Disease: Similarity and Dissimilarity of Molecular Alerts
Current Neuropharmacology Current Concepts on Selected Plant Secondary Metabolites With Promising Inhibitory Effects Against Enzymes Linked to Alzheimer’s Disease
Current Medicinal Chemistry Insulin and the Brain
Current Diabetes Reviews The Interactions Between Alzheimer’s Disease and Major Depression: Role of Ca<sup>2+</sup> Channel Blockers and Ca<sup>2+</sup>/cAMP Signalling
Current Drug Research Reviews Antipsoriatic Drug Development: Challenges and New Emerging Therapies
Recent Patents on Inflammation & Allergy Drug Discovery Myogenic Tone as a Therapeutic Target for Ischemic Stroke
Current Vascular Pharmacology Platelet Function and Antiplatelet Therapy in Cardiovascular Disease: Implications of Genetic Polymorphisms
Current Vascular Pharmacology Differential Regulation of microRNAs in Patients with Ischemic Stroke
Current Neurovascular Research An Insight into the Recent Diabetes Trials: What is the Best Approach to Prevent Macrovascular and Microvascular Complications?
Current Diabetes Reviews Vascular Pharmacotherapy and Dementia
Current Vascular Pharmacology Transport Mechanisms at the Blood-Cerebrospinal-Fluid Barrier: Role of Megalin (LRP2)
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Cognition and Neuropathology in Aging: Multidimensional Perspectives from the Rush Religious Orders Study and Rush Memory and Aging Project
Current Alzheimer Research Phosphodiesterase Inhibitors as Potential Cognition Enhancing Agents
Current Topics in Medicinal Chemistry